Mc-Val-Cit-PABC-PNP: Technical Guidance for Cathepsin-Cleavable ADC Linker Use

What This Product Solves

Mc-Val-Cit-PABC-PNP is engineered as a cathepsin cleavable ADC peptide linker for research applications in targeted drug delivery. Its core function is to provide a reliable, lysosome-activated cleavage site within antibody-drug conjugates (ADCs), facilitating the specific release of cytotoxic payloads only after internalization into target cells. This selectivity is achieved through the inclusion of the Val-Cit dipeptide, a recognized cathepsin B substrate linker. By integrating a self-immolative PABC spacer, Mc-Val-Cit-PABC-PNP ensures efficient and clean payload release following protease-mediated cleavage. The linker is structurally analogous to those used in FDA-approved ADCs such as brentuximab vedotin, supporting established strategies in antibody-drug conjugate synthesis for cancer research. For further context, an internal article (Mc-Val-Cit-PABC-PNP: ADC Peptide Linker for Targeted Delivery) outlines the mechanism by which this linker enables precise cytotoxic release and highlights its optimal fit for lysosomally activated ADCs.

Protocol Parameters

• Solubility in DMSO: ≥36.9 mg/mL | Prepare concentrated stock solutions for ADC conjugation workflows; not compatible with aqueous or ethanol-based protocols. | Ensures adequate linker concentration for efficient coupling steps. | product dossier
• Storage Temperature: -20°C (solid) | Maintain at -20°C prior to use; minimize repeated freeze-thaw cycles. | Preserves chemical stability and prevents hydrolysis or degradation. | product dossier
• Solution Stability: Use promptly after preparation; long-term storage of solutions is not recommended | Prepare fresh aliquots for each experiment; avoid extended storage of DMSO solutions. | Reduces risk of linker degradation and maintains reactivity for conjugation. | product dossier
• Purity: 98.00% (as supplied) | Use directly in research ADC syntheses without further purification unless required by downstream QC. | High purity minimizes side reactions and improves reproducibility. | product dossier
• Recommended Handling: Avoid moisture and direct light exposure | Weigh and dissolve under dry, inert conditions where possible; use amber vials for light-sensitive workflows. | Prevents degradation and ensures maximum linker integrity. | workflow recommendation

Workflow Setup and QC Checklist

To ensure consistent results with Mc-Val-Cit-PABC-PNP in antibody-drug conjugate synthesis, apply the following workflow and quality control measures:

• Weighing and Dissolution: Accurately weigh the required amount of solid linker using an analytical balance. Dissolve in anhydrous DMSO to achieve the desired stock concentration, ensuring complete dissolution by gentle mixing. Avoid exposure to humidity during handling.
• Immediate Use: Once dissolved, use the DMSO stock promptly in conjugation reactions. If aliquoting, store at -20°C and use as soon as feasible, as prolonged storage can compromise linker activity.
• Conjugation Conditions: Optimize reaction pH and temperature according to the antibody and payload chemistry. The linker is not soluble in water or ethanol, so avoid aqueous buffer steps until after conjugation.
• QC by Analytical HPLC or Mass Spectrometry: Post-conjugation, assess product integrity and conjugation efficiency using analytical HPLC or LC-MS. Confirm that the expected mass shift or retention time matches the designed ADC construct.
• Documentation: Record lot numbers, preparation date, and storage conditions for traceability and reproducibility.

Common Failure Modes and Fixes

• Incomplete Dissolution in Solvent: If undissolved particulates remain after addition to DMSO, verify the dryness of both the solvent and the linker. Warm gently (not exceeding 37°C) to facilitate dissolution. Do not attempt to dissolve in water or ethanol.
• Linker Degradation During Storage: Observed by color change or precipitation in DMSO solution. Always prepare fresh solutions and avoid repeated freeze-thaw cycles. Store solid material tightly sealed at -20°C.
• Low Conjugation Efficiency: May result from suboptimal reaction conditions or degraded linker. Confirm the purity and freshness of all reagents; optimize molar ratios and ensure antibody is in a suitable buffer (e.g., free of primary amines if using NHS-activated payloads).
• Unexpected Side Products: Sometimes detected by HPLC/MS. Review compatibility of payload and antibody with linker chemistry; ensure all glassware is clean and solvents are anhydrous.

Scope and Limitations

Mc-Val-Cit-PABC-PNP is suitable for research workflows involving synthetic antibody-drug conjugate assembly where a cathepsin B substrate linker is required. Its high solubility in DMSO and chemical structure enable its use in lysosomal cleavage linker strategies for targeted drug delivery research. However, this linker is not appropriate for applications requiring aqueous or ethanol solubility, nor for diagnostic or therapeutic use in humans or animals (Mc-Val-Cit-PABC-PNP). For further technical background, the internal article "Mc-Val-Cit-PABC-PNP: ADC Peptide Linker for Targeted Delivery" discusses its optimal use in lysosomally activated ADCs and cautions against applications outside this domain. Adherence to storage and handling recommendations is essential for maintaining product integrity. Researchers should validate all protocols within the intended research context and consult institutional guidelines for ADC handling.

Conclusion

Mc-Val-Cit-PABC-PNP provides a robust, cathepsin-cleavable linker option for the synthesis of targeted antibody-drug conjugates in cancer research. By following recommended solubility, storage, and QC practices, researchers can achieve reliable and reproducible results. For more detailed specifications or to buy Mc-Val-Cit-PABC-PNP peptide linker, visit APExBIO. This product is intended strictly for scientific research and should not be used for diagnostic or medical applications.